{"product_id":"recombinant-human-insulin-like-growth-factor-1-receptor-igf1r-partial-active-bhp10515348","title":"Recombinant Human Insulin-like growth factor 1 receptor (IGF1R), partial (Active)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eRecombinant Human Insulin-like growth factor 1 receptor (IGF1R), partial (Active) is a recombinant protein preparation derived from Homo sapiens (Human). It is commonly used as a defined reagent for assay development, binding studies, and analytical controls where consistent protein specifications are required.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpressed region:\u003c\/strong\u003e 31-932aa.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e Mammalian cell (may influence folding and post-translational modifications).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTag\/format:\u003c\/strong\u003e C-terminal 10xHis-tagged; Lyophilized powder.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpected size:\u003c\/strong\u003e 104.2 kDa (as provided).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Greater than 90% as determined by SEC-HPLC. Greater than 95% as determined by SDS-PAGE.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eRegion choice, expression system, and tag\/format can influence folding, post-translational modifications, and interaction behavior in downstream assays.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eReceptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1\/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT\/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT\/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2\/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase\/signal transducer and activator of transcription pathway (JAK\/STAT). Phosphorylation of JAK proteins can lead to phosphorylation\/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK\/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5\/ASK1, which is able to directly associate with the IGF1R. When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eDomain- and isoform-aware assay design to improve biological interpretation across model systems.\u003c\/li\u003e\n\u003cli\u003eQuantitative workflows emphasizing calibration standards, spike-in controls, and cross-lot comparability.\u003c\/li\u003e\n\u003cli\u003eIn vitro binding\/kinetics profiling (SPR\/BLI) to connect biochemical interactions with cellular phenotypes.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003ePrepare aliquots of IGF1R for reproducible in vitro assays (minimize freeze–thaw).\u003c\/li\u003e\n\u003cli\u003eUse IGF1R as a calibration standard in quantitative assays (standard curve setup).\u003c\/li\u003e\n\u003cli\u003eMeasure binding interactions to IGF1R by SPR\/BLI (kinetic profiling in vitro).\u003c\/li\u003e\n\u003cli\u003eGenerate antibodies to IGF1R and benchmark specificity in ELISA\/WB (control samples).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpret results in the context of the biological system, assay format, and any known domain\/isoform constraints for the target.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eConsider species- and isoform-specific differences when comparing results across models or homologs.\u003c\/li\u003e\n\u003cli\u003eFor quantitative assays, include appropriate negative controls and matrix-matched spike-in concepts to assess non-specific signal.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProtKB entry (P08069) — UniProt: https:\/\/www.uniprot.org\/uniprotkb\/P08069 - NCBI Gene search (IGF1R) — NCBI: https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=IGF1R - PubMed search — NLM: https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=IGF1R - Reactome pathway browser — Reactome: https:\/\/reactome.org\/ - InterPro protein family resource — EMBL-EBI: https:\/\/www.ebi.ac.uk\/interpro\/ --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53059286991213,"sku":"CSB-MP011087HU1-1MG","price":2212.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53059418587501,"sku":"CSB-MP011087HU1-100UG","price":342.0,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53059418620269,"sku":"CSB-MP011087HU1-20UG","price":136.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-MP011087HU1-SDS.jpg?v=1772280282","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-insulin-like-growth-factor-1-receptor-igf1r-partial-active-bhp10515348","provider":"BioHippo","version":"1.0","type":"link"}